These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1690 related items for PubMed ID: 27357817

  • 1. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C, Lee R.
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [Abstract] [Full Text] [Related]

  • 2. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V.
    J Ovarian Res; 2019 Jan 28; 12(1):9. PubMed ID: 30691488
    [Abstract] [Full Text] [Related]

  • 3. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    Tan DS, Kaye SB.
    Am Soc Clin Oncol Educ Book; 2015 Jan 28; ():114-21. PubMed ID: 25993149
    [Abstract] [Full Text] [Related]

  • 4. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    Tewari KS, Eskander RN, Monk BJ.
    Clin Cancer Res; 2015 Sep 01; 21(17):3829-35. PubMed ID: 26169965
    [Abstract] [Full Text] [Related]

  • 5. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    Miller RE, Ledermann JA.
    Clin Adv Hematol Oncol; 2016 Sep 01; 14(9):704-11. PubMed ID: 27673289
    [Abstract] [Full Text] [Related]

  • 6. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.
    Lancet Oncol; 2015 Jan 01; 16(1):87-97. PubMed ID: 25481791
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW, Tewari KS.
    Curr Treat Options Oncol; 2016 Mar 01; 17(3):12. PubMed ID: 26931795
    [Abstract] [Full Text] [Related]

  • 9. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
    Gadducci A, Guerrieri ME.
    Anticancer Res; 2016 May 01; 36(5):2055-64. PubMed ID: 27127105
    [Abstract] [Full Text] [Related]

  • 10. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA, Drew Y, Kristeleit RS.
    Eur J Cancer; 2016 Jun 01; 60():49-58. PubMed ID: 27065456
    [Abstract] [Full Text] [Related]

  • 11. Ovarian cancer treatment in mutation carriers/BRCAness.
    Lorusso D, Perotto S.
    Minerva Ginecol; 2016 Oct 01; 68(5):566-78. PubMed ID: 26785283
    [Abstract] [Full Text] [Related]

  • 12. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O, Arslan C, Altundag K.
    Expert Opin Pharmacother; 2015 Oct 01; 16(18):2751-8. PubMed ID: 26485111
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
    Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, Pautier P, Ledermann JA, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Colombo N, Park-Simon TW, Tamura K, Sonke GS, Freimund AE, Lee CK, Pujade-Lauraine E.
    Ann Oncol; 2022 Oct 01; 33(10):1021-1028. PubMed ID: 35772665
    [Abstract] [Full Text] [Related]

  • 15. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.
    Clin Cancer Res; 2017 Aug 01; 23(15):4086-4094. PubMed ID: 28223274
    [Abstract] [Full Text] [Related]

  • 16. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy.
    Zhang N, Zheng H, Gao Y, Shu T, Wang H, Cai Y.
    J Ovarian Res; 2024 Mar 05; 17(1):55. PubMed ID: 38444005
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, Ali-Fehmi R, Buekers T, Munkarah AR, Rattan R.
    Gynecol Oncol; 2016 Aug 05; 142(2):323-31. PubMed ID: 27282964
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.
    Oncotarget; 2017 Jul 18; 8(29):47154-47160. PubMed ID: 28454085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 85.